Spyre Therapeutics (SYRE) Assets (2015 - 2026)

Spyre Therapeutics' Assets history runs 12 years deep, the most recent figure standing at $764.0 million for Q1 2026.

• Quarterly Assets rose 34.08% year-over-year to $764.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $764.0 million (up 34.08% YoY) and the FY2025 annual result came in at $777.8 million, up 27.82% from the prior year.
• Assets was $764.0 million for Q1 2026 at Spyre Therapeutics, down from $777.8 million in the prior quarter.
• Across five years, Assets topped out at $777.8 million in Q4 2025 and bottomed at $52.5 million in Q1 2023.
• A 5-year average of $370.9 million and a median of $421.1 million in 2024 frame the typical range for Assets.
• Annual changes were most pronounced in 2022 — Assets tumbled 49.17% — and 2024, when it surged 829.6%.
• Spyre Therapeutics' Assets stood at $71.1 million in 2022, then jumped by 380.52% to $341.9 million in 2023, then jumped by 77.99% to $608.5 million in 2024, then grew by 27.82% to $777.8 million in 2025, then slipped by 1.78% to $764.0 million in 2026.
• Business Quant data shows SYRE's Assets at $764.0 million in Q1 2026, $777.8 million in Q4 2025, and $504.6 million in Q3 2025.